In Brief: Oncor
This article was originally published in The Gray Sheet
Executive Summary
Oncor: Receives a $750,000 Phase II SBIR (Small Business Innovation Research) grant from NIH. The grant will go towards Oncor's analysis of human telomeres -- a cap at the end of human chromosomes essential for the maintenance of their structure and stability. Oncor plans to develop a panel of chromosome-specific telomere gene probes that the company anticipates will be helpful in "elucidating the role of telomeres in cancer and other genetic disorders"...